Molecular Imaging Tumor Volume of Somatostatin Receptor (MITVSSR) on 68Ga-DOTATATE PET/CT, dosimetry and predictors of overall survival and response in unresectable neuroendocrine neoplasms treated with Peptide Receptor Radionuclide Therapy (PRRT)

#3470

Introduction: PRRT delivers targeted radionuclide therapy to Neuroendocrine Neoplasms (NENs) with high SSR expression.

Aim(s): To evaluate prognostic factors of response and overall survival (OS) in patients with comprehensive post-treatment dosimetry as part of PRRT.

Materials and methods: Patients with gastroenteropancreatic NEN who received 177Lu DOTATATE (Jul 2010 - Jan 2019) were retrospectively reviewed. MITVSSR was measured on pre- and 3-month post- PRRT GaTate PET/CT with segmentation based on 1.5 liver SUVmean+2SD. Dosimetry measurements of the index lesion were performed at 24 hrs post-PRRT quantitative SPECT/CTs for each cycle using population pharmacokinetic modelling.

Conference:

Presenting Author:

Authors: Alipour R, Jackson P, Callahan J, Bressel M, Hogg A,

Keywords: PRRT, dosimetry, survival, response,